Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics
PSTX Price/Volume Stats
| Current price | $2.02 | 52-week high | $4.27 |
| Prev. close | $2.00 | 52-week low | $1.54 |
| Day low | $1.95 | Volume | 641,400 |
| Day high | $2.07 | Avg. volume | 712,730 |
| 50-day MA | $3.20 | Dividend yield | N/A |
| 200-day MA | $2.67 | Market Cap | 194.91M |
PSTX Stock Price Chart Interactive Chart >
Poseida Therapeutics Inc. (PSTX) Company Bio
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Latest PSTX News From Around the Web
Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023. |
Poseida Therapeutics to Present at Two Upcoming Investor ConferencesPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November: |
PSTX Price Returns
| 1-mo | -33.55% |
| 3-mo | -26.81% |
| 6-mo | -3.81% |
| 1-year | -29.12% |
| 3-year | -77.30% |
| 5-year | N/A |
| YTD | -39.88% |
| 2023 | -36.60% |
| 2022 | -22.17% |
| 2021 | -37.92% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...